2023
Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy
Hoppe B, McCarten K, Pei Q, Kessel S, Alazraki A, Mhlanga J, Lai H, Eutsler E, Hodgson D, Roberts K, Charpentier A, Keller F, Voss S, Wu Y, Cho S, Kelly K, Castellino S. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 116: 1025-1030. PMID: 36868525, PMCID: PMC10363760, DOI: 10.1016/j.ijrobp.2023.02.020.Peer-Reviewed Original ResearchConceptsCentral reviewDeauville scoreCentral imaging reviewRadiation therapyResponse assessmentHodgkin's lymphomaImaging reviewInstitutional reviewFluorodeoxyglucose positron emission tomography/High-risk Hodgkin lymphomaPositron emission tomography responseConcordance rateEmission tomography/Real-time central reviewCohen κ statisticAreas of diseaseSystemic therapyTreating institutionPediatric patientsLymphoma trialsTomography responseTomography/Treatment allocationClinical trialsPatients
2021
The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity
Lo A, Liu A, Liu Q, Yasui Y, Castellino S, Kelly K, Herrera A, Friedberg J, Friedman D, Schwartz C, Bergeron-Gravel S, Dama H, Roberts K, Constine L, Hodgson D. The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity. Blood 2021, 138: 881. DOI: 10.1182/blood-2021-147678.Peer-Reviewed Original ResearchInvolved site radiotherapyCardiac radiation doseInvolved-field radiotherapyChildhood Cancer Survivor StudyPositron emission tomographyMediastinal radiotherapyChildren's Oncology GroupDoxorubicin doseCumulative incidenceCardiac toxicityCardiac diseaseRT useCardiac riskCardiac disease riskBulk diseaseOncology GroupLymphoma trialsTrial protocolRadiation doseLong-term cardiac riskDisease riskCumulative doxorubicin doseImpact of nivolumabLate cardiac toxicityMean heart dosePediatric classical Hodgkin lymphoma
Lo AC, Dieckmann K, Pelz T, Gallop‐Evans E, Engenhart‐Cabillic R, Vordermark D, Kelly KM, Schwartz CL, Constine LS, Roberts K, Hodgson D. Pediatric classical Hodgkin lymphoma. Pediatric Blood & Cancer 2021, 68: e28562. PMID: 33818890, DOI: 10.1002/pbc.28562.Peer-Reviewed Original ResearchConceptsClassical Hodgkin lymphomaChildren's Oncology GroupPediatric classical Hodgkin lymphomaHodgkin's lymphomaRadiation therapyOncology GroupUtilization of RTHigh-risk patientsBulk of diseaseHigh cure ratesUniformly fatal diseaseLong-term toxicityIntensity of treatmentEuroNet-PHLB symptomsRisk patientsCurable cancerLymphoma trialsRT volumeCure rateTumor stageImmunoregulatory drugsTrial groupChemotherapy agentsHL management